Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP5 | P45974 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | KMO | O15229 | 3/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10708232 | 0.86 | ALDH1A1 (0.50) | USP5KMT2ANR4A2KMOPKM | |
| SCHEMBL727064 | 0.84 | TSHR (0.59) | USP5KMT2ANR4A2KMOPKM | |
| SCHEMBL3148795 | 0.84 | NR4A2 (0.53) | USP5KMT2ANR4A2PKMTSHR | |
| SCHEMBL11637468 | 0.81 | USP5 (0.50) | USP5KMT2ANR4A2PKMTSHR | |
| SCHEMBL10744419 | 0.80 | KDM4E (0.51) | KMT2AKDM4EKMOTSHRLMNA | |
| SCHEMBL11536711 | 0.79 | KMT2A (0.58) | USP5KMT2ANR4A2PKMTSHR | |
| SCHEMBL11352711 | 0.79 | MAPT (0.59) | USP5KMT2ANR4A2PKMTSHR | |
| SCHEMBL11089924 | 0.79 | USP5 (0.49) | USP5KMT2ANR4A2PKMTSHR | |
| SCHEMBL5313540 | 0.79 | USP5 (0.49) | USP5KMT2ANR4A2PKMTSHR | |
| SCHEMBL11636679 | 0.79 | KMT2A (0.49) | USP5KMT2ANR4A2KDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2066628-B1 | 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | SANOFI AVENTIS (FR) | 2010-10-20 | — | — | EP | disclosed |
| CN-101495449-A | 2-phenyl-indoles as prostaglandin D2 receptor antagonists | SANOFI AVENTIS (FR) | 2009-07-29 | — | — | CN | disclosed |
| US-20090176804-A1 | 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2009-07-09 | — | — | US | disclosed |
| EP-2066628-A1 | 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | Sanofi-Aventis (FR) | 2009-06-10 | — | — | EP | disclosed |
| CN-101146770-A | 2-phenyl indoles as prostaglandin D2 receptor antagonists | AVENTIS PHARMA INC (US) | 2008-03-19 | — | — | CN | disclosed |
| WO-2008014186-A1 | 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2008-01-31 | — | — | WO | disclosed |
| US-20070265278-A1 | 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-11-15 | — | — | US | disclosed |
| EP-1844011-A1 | 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | Aventis Pharmaceuticals Inc. (US) | 2007-10-17 | — | — | EP | disclosed |
| WO-2006081343-A1 | 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2006-08-03 | — | — | WO | disclosed |
| US-4929643-A | Benzenesulfonamide derivatives and a process for the preparation thereof | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-05-29 | — | — | US | disclosed |
| US-4849444-A | Benzenesulfonamide derivatives and a process for the medical use thereof | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-07-18 | — | — | US | disclosed |
| US-4082843-A | 3-(3-(3-Substituted amino-2-hydroxypropoxy)phenyl)-6-hydrazino pyridazines and their use as vasodilators and β-adrenergic blocking agents | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1978-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265278-A1 | 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | PTGDR2, PTGDR, CYSLTR2 | USP5 2143/4885KMT2A 4133/4885NR4A2 1593/4885 |
| US-20090176804-A1 | 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | PTGER2, PTGDR2, CYSLTR2 | USP5 2212/4885KMT2A 3055/4885NR4A2 1508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.